|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, it was discovered that PEG10 isoforms promote the progression of prostate cancer to a highly lethal androgen receptor (AR)-negative phenotype.
|
31530569 |
2019 |
|
Progression of prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
miR-103a-2-5p/miR-30c-1-3p inhibits the progression of prostate cancer resistance to androgen ablation therapy via targeting androgen receptor variant 7.
|
30963631 |
2019 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The androgen receptor (AR) signaling axis plays a pivotal role in the progression of prostate cancer.
|
31239713 |
2019 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, Sertad1 may represent a novel therapeutic target for the treatment of AR-positive PCa.
|
30230528 |
2019 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The androgen receptor (AR) is known to be involved in the pathogenesis and progression of prostate cancer.
|
31689899 |
2019 |
|
Progression of prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Castration-resistant progression of prostate cancer is a major cause of prostate cancer mortality, and increased expression and activity of the full-length and the splice variants of androgen receptor (AR) have been indicated to drive castration resistance.
|
30905075 |
2019 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Androgen Receptor (AR) pathway plays a major role in both the pathogenesis and progression of prostate cancer.
|
30209993 |
2019 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The androgen receptor (AR) plays key roles in the development of prostate tissue and the development and progression of prostate cancer (PC).
|
31520575 |
2019 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although androgen receptor (AR) signaling plays a key role in the development and progression of prostate cancer, aberrations in other molecular pathways also contribute to the disease, making it essential to identify and develop drugs against novel targets, both for the prevention and treatment of prostate cancer.
|
28597850 |
2019 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen receptor (AR) signaling functions as a core driving force for the progression of prostate cancer (PCa), and AR has been proved to be an effective therapeutic target even for castration-resistant prostate cancer (CRPC).
|
29388326 |
2018 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
HDL significantly reduced basal and H<sub>2</sub>O<sub>2</sub>-induced oxidative stress in normal, androgen receptor (AR)-positive and AR-null PCa cell lines.
|
29396407 |
2018 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Androgen Receptor (AR) is a key molecule in the development, maintenance and progression of prostate cancer (PC).
|
29423094 |
2018 |
|
Progression of prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Given the significant importance of androgen receptor and a few known NRs in the progression of prostate cancer, we surveyed the expression profiles of the entire NR superfamily in three-dimensional cultured prostatospheroids derived from different prostate cancer cell lines and a tumor xenograft model of castration-resistant prostate cancer VCaP-CRPC by quantitative real-time RT-PCR.
|
29042395 |
2018 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the role of AR in PCa metastasis, we examined AR expression level in primary and metastatic PCa by analyzing gene array data of 378 primary prostate tumors and 120 metastatic prostate tumors from Oncomine, as well as carrying out immunohistochemical (IHC) staining of 56 prostate cancer samples.
|
30142696 |
2018 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen receptor (AR) plays a crucial role in the development and progression of prostate cancer.
|
29572225 |
2018 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen receptor (AR) plays a critical role in the development and progression of prostate cancer (PCa).
|
30555332 |
2018 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The urgent need therefore continues for novel classes of AR inhibitors that can overcome drug resistance, especially since AR signalling remains important even in late-stage advanced PCa.
|
30193215 |
2018 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
There was no significant difference in the mRNA and protein levels of iNOS, VEGF, AR and IL-2, IL-8 and TNF-α between PCa and BPH+HP groups (p > .05). iNOS, VEGF, AR and IL-2, IL-8 and TNF-α are involved in the malignant transformation of prostate tissue and play an important role in the development and progression of Prostate cancer (PCa).
|
29441606 |
2018 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The androgen receptor (AR) is a ligand-activated nuclear receptor that plays a critical role in normal prostate physiology, as well as in the development and progression of prostate cancer.
|
29934310 |
2018 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, we discuss about the crosstalk between these three critical pathways as well as how the anti-inflammatory antioxidant phytochemicals like sulforaphane (SFN) and curcumin (CUR), which can also target AR, can be ideal candidates in the chemoprevention of PCa.
|
30257470 |
2018 |
|
Progression of prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Collectively, <i>LINC00844</i> is a novel coregulator of AR that plays a central role in the androgen transcriptional network and the development and progression of prostate cancer.
|
30115758 |
2018 |
|
Progression of prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Androgen receptor (AR) is a transcription factor that plays a key role in the initiation and progression of prostate cancer. p53, a major tumor suppressor that is rarely mutated in early-stages of prostate cancer, is often deregulated during prostate cancer progression.
|
29464071 |
2018 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen receptor (AR) mediates initiation and progression of prostate cancer (PCa); AR-driven transcription is activated by binding of androgens to the ligand-binding domain (LBD) of AR.
|
28977932 |
2017 |
|
Progression of prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This includes downregulating levels of the AR-V7, a drug-resistance-related AR splice variant that is important in the progression of prostate cancer.
|
28129131 |
2017 |
|
Progression of prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen receptor (AR) plays a crucial role in the development and progression of prostate cancer (PCa).
|
28185938 |
2017 |